NCT03806153

Brief Summary

In France, nearly 3% of children are conceived by the technique of Assisted Reproductive Medicine, of which nearly 70% by in vitro fertilization (IVF). The rates of clinical pregnancy by oocyte retrieval or embryo transfer have not changed much. The use of mono-embryo transfer reduces the risk of multiple pregnancies and associated obstetric complications. The choice of embryo to transfer or freeze is a key element in improving the chances of success of IVF. It is usually based on conventional morphological criteria (reference method) that are punctual, qualitative and subjective. However, embryo morphology at early stages has little predictive value for obtaining a late-stage embryo and its chances of implantation. The recent use of time-lapse technology during embryonic culture makes it possible to associate morphological criteria with continuous monitoring of the kinetics of embryonic development. The choice of the embryo to be transferred is then made according to morphokinetic criteria (conventional morphological criteria to which are added the data of the kinetics of embryonic development). Two recent retrospective studies give contradictory results, the first shows higher birth rates in the group of embryos selected according to conventional morphological criteria, the second concludes that morphokinetic analysis is superior. Morphokinetic criteria would also be more objective and reproducible. However, the use of morphokinetic parameters remains controversial in the literature.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
520

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 16, 2019

Completed
1.8 years until next milestone

Study Start

First participant enrolled

October 26, 2020

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

February 20, 2026

Status Verified

February 1, 2026

Enrollment Period

5.3 years

First QC Date

January 14, 2019

Last Update Submit

February 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • The primary endpoint of this study will be the live birth rate by fresh embryo transfer(s).

    36 months

Study Arms (2)

Conventional morphology arm (reference method)

ACTIVE COMPARATOR
Other: Morphokinetic

Morphokinetic arm

EXPERIMENTAL
Other: Morphokinetic

Interventions

The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).

Conventional morphology arm (reference method)Morphokinetic arm

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • For the couple:
  • Couple whose two members are 18 years old and over,
  • Couple whose two members are affiliated to a social security scheme,
  • Couple whose two members read and understood the newsletter and signed the consent form for their participation in this research.
  • For the conditions of realization of the ICSI attempt:
  • Couple supported for a 1st or 2nd attempt at in vitro fertilization with sperm microinjection (ICSI) for male infertility,
  • In vitro fertilization attempt performed with micro-injection of fresh ejaculated spermatozoa.
  • For the man:
  • Couple whose man has an alteration of at least one of the sperm parameters according to the WHO (WHO, 2010) for the number, concentration, vitality, mobility or morphology according to the modified David classification (Auger and Eustache, 2000).

You may not qualify if:

  • For the couple:
  • Couple whose wife is under 18 and over 42 and / or the male is under 18 and over 59
  • Couple already included in the protocol "EMCIMO" for a previous attempt,
  • Couple of which one or both members is deprived by an administrative or judicial decision or subject to a legal measure of protection of the majors (safeguard of justice or tutelage or curatorship),
  • Couple where one or both members do not speak or understand French.
  • For the conditions of realization of the ICSI attempt:
  • \- In vitro fertilization attempt with the micro-injection of testicular spermatozoa, epididymal, previously frozen or resulting from a retrograde ejaculation.
  • For the man:
  • Severe oligozoospermia (\<100,000 spermatozoa / ejaculate).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU CAEN

Caen, 14033, France

RECRUITING

Chu Rouen

Rouen, 76031, France

RECRUITING

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2019

First Posted

January 16, 2019

Study Start

October 26, 2020

Primary Completion

March 1, 2026

Study Completion

March 1, 2026

Last Updated

February 20, 2026

Record last verified: 2026-02

Locations